These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 33219064)

  • 1. Predictors of Family Medicine Patient Retention in Opioid Medication-Assisted Treatment.
    Justesen K; A Hooker S; Sherman MD; Lonergan-Cullum M; Nissly T; Levy R
    J Am Board Fam Med; 2020; 33(6):848-857. PubMed ID: 33219064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-year Retention Rates With Office-based Treatment of Buprenorphine for Opioid Use Disorder in a Private Family Medicine Practice.
    Cope K; DeMicco J; Salib J; Michael M; Yakoub P; Daoud K; Cope R
    J Addict Med; 2022 Nov-Dec 01; 16(6):716-721. PubMed ID: 35913992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrating Buprenorphine Treatment for Opioid Use with Primary Care is Associated with Greater Retention in Treatment.
    Mirer AG; Tiemstra JD; Hammes NE; Cloum HM; LaFavor KJ
    J Am Board Fam Med; 2022; 35(1):206-208. PubMed ID: 35039431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication-Assisted Treatment for Opioid Use Disorder in a Rural Family Medicine Practice.
    Deyo-Svendsen M; Cabrera Svendsen M; Walker J; Hodges A; Oldfather R; Mansukhani MP
    J Prim Care Community Health; 2020; 11():2150132720931720. PubMed ID: 32507023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Training in office-based opioid treatment with buprenorphine in US residency programs: A national survey of residency program directors.
    Tesema L; Marshall J; Hathaway R; Pham C; Clarke C; Bergeron G; Yeh J; Soliman M; McCormick D
    Subst Abus; 2018; 39(4):434-440. PubMed ID: 29513136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Primary Care in Improving Access to Medication-Assisted Treatment for Rural Medicaid Enrollees with Opioid Use Disorder.
    Cole ES; DiDomenico E; Cochran G; Gordon AJ; Gellad WF; Pringle J; Warwick J; Chang CH; Kim JY; Kmiec J; Kelley D; Donohue JM
    J Gen Intern Med; 2019 Jun; 34(6):936-943. PubMed ID: 30887440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact on Future Prescribing Patterns of Opioid Use Disorder (OUD) Education and Waiver Provision During Residency.
    Boggiano V; Gilmore Wilson C; Fagan EB; Kirk J; Bossenbroek-Fedoriw K; Tak CR
    J Am Board Fam Med; 2020; 33(6):998-1003. PubMed ID: 33219079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis.
    Ma J; Bao YP; Wang RJ; Su MF; Liu MX; Li JQ; Degenhardt L; Farrell M; Blow FC; Ilgen M; Shi J; Lu L
    Mol Psychiatry; 2019 Dec; 24(12):1868-1883. PubMed ID: 29934549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations of retention on buprenorphine for opioid use disorder with patient characteristics and models of care in the primary care setting.
    Bailey SR; Lucas JA; Angier H; Cantone RE; Fleishman J; Garvey B; Cohen DJ; Rdesinski RE; Gordon L
    J Subst Abuse Treat; 2021 Dec; 131():108548. PubMed ID: 34244013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of a novel office-based opioid treatment program in an internal medicine resident continuity practice.
    Pytell JD; Buresh ME; Graddy R
    Addict Sci Clin Pract; 2019 Dec; 14(1):46. PubMed ID: 31856915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nine-year substance use treatment outcomes with buprenorphine for opioid use disorder in a federally qualified health center.
    Haddad M; Coman E; Bifulco L
    Drug Alcohol Depend; 2024 Apr; 257():111252. PubMed ID: 38484404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementation of office-based buprenorphine treatment for opioid use disorder.
    Carroll E
    J Am Assoc Nurse Pract; 2021 Mar; 34(1):196-204. PubMed ID: 33767120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integration of Buprenorphine Treatment with Primary Care: Comparative Effectiveness on Retention, Utilization, and Cost.
    Hsu YJ; Marsteller JA; Kachur SG; Fingerhood MI
    Popul Health Manag; 2019 Aug; 22(4):292-299. PubMed ID: 30543495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective Review of a Novel Approach to Buprenorphine Induction in the Emergency Department.
    Dunkley CA; Carpenter JE; Murray BP; Sizemore E; Wheatley M; Morgan BW; Moran TP; Steck A
    J Emerg Med; 2019 Aug; 57(2):181-186. PubMed ID: 31060846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrating Buprenorphine Treatment Into Family Medicine Resident Clinic.
    Tiemstra JD; Walsh LH
    Fam Med; 2020 Oct; 52(9):653-655. PubMed ID: 33030722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-Year Retention in Buprenorphine Treatment for Opioid Use Disorder Among Privately Insured Adults.
    Manhapra A; Agbese E; Leslie DL; Rosenheck RA
    Psychiatr Serv; 2018 Jul; 69(7):768-776. PubMed ID: 29656707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia.
    Burns L; Gisev N; Larney S; Dobbins T; Gibson A; Kimber J; Larance B; Mattick RP; Butler T; Degenhardt L
    Addiction; 2015 Apr; 110(4):646-55. PubMed ID: 25516077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of Medication Utilization for Opioid Use Disorder Among Medicaid-Insured HIV Patients in New York.
    Choi S; Yerneni R; Healy S; Goyal M; Neighbors CJ
    Am J Addict; 2020 Mar; 29(2):151-154. PubMed ID: 31951083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between Participation in Counseling and Retention in a Buprenorphine-Assisted Treatment Program for People Experiencing Homelessness with Opioid Use Disorder.
    Berry ARW; Finlayson TL; Mellis LM; Urada LA
    Int J Environ Res Public Health; 2021 Oct; 18(21):. PubMed ID: 34769591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of engagement and retention in care at a low-threshold substance use disorder bridge clinic.
    Wakeman SE; McGovern S; Kehoe L; Kane MT; Powell EA; Casey SK; Yacorps GM; Irvin JR; Rodriguez W; Regan S
    J Subst Abuse Treat; 2022 Oct; 141():108848. PubMed ID: 35926256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.